Generic Injectable Market

2019 Analysis and Review of Generic Injectable Market by Product - Monoclonal Antibodies, Immunoglobulins, Cytokines, Insulin, Peptide Hormones, Blood Factors, Peptide Antibiotics, Vaccines, Small Molecule Antibiotics, Chemotherapy Agents, and Others for 2019 - 2029

Manufacturers Prefer Monoclonal Antibodies to Develop Generic Injectables

Given their higher biosimilar capabilities and cost benefits over branded injectable drugs, demand for monoclonal antibodies (mAbs) stays atop in the generic injectable market. Procuring around a quarter of overall market value, manufacturers prefer mAb drugs for treating various chronic disorders, including cancer and other autoimmune diseases. Rising prominence of single-use technologies and closed delivery systems are transforming vaccine manufacturing, particularly in addressing the challenge of sterilization. Market players are thus driving innovations in the development and delivery of vaccines.

Developed Regions Maintain their Primacy

Capturing a significant chunk of total market revenue, collectively, North America and Europe are the hub of value-creation prospects for manufacturers. The presence of a well-established healthcare system and increasing rate of drug approvals are auguring well for the generic injectable market in these developed regions.

Further, North America and Europe would share nearly identical divide in the market landscape by 2029 end. Driven by drastic upsurge in production capacity and technology intervention in the pharmaceutical industry, manufacturers are also targeting Asia for further investment opportunities.

Reimagining Supplier Ecosystems with CMOs

Contract manufacturing organizations (CMOs) play an instrumental role in spurring network disruptions in the healthcare vertical. Moreover, recent projections suggest that, CMOs are likely to flourish nearly twice that of the entire medtech industry in the near future.

Market incumbents are outsourcing the manufacturing of generic injectable drugs to CMOs in order to ensure significant savings in capital expenses (CAPEX). Furthermore, with a proper approach, CMOs help them manage volatilities in demand and tackle supply risks. As such, players in the generic injectable market would be well placed to expand their customer base with quality-focused products and services.

How Growth will Unfold

Small molecules have been a mainstay in the manufacturing of generic injectable drugs, primarily attributable to the favorable regulatory framework. However, large molecule drugs, or biologic drugs, are emerging as a major shake-up in the biotechnology industry, owing to their greater specificity and safety profile in injectable drug delivery. By 2022, large molecule generic injectables will outperform the small molecule iterations. These paradigm shifts are compelling generic injectable manufacturers to re-think every facet of their approaches.


What are the factors contributing to the growth of the generic injectable market?

Growing focus on targeted therapies and biologics, particularly in the area of cancer, is increasing the need for generic injectable drugs. Biological injectable drugs hold a notable share of the generic injectable market. Adoption of generic injectables in small molecules is anticipated to gain significant traction.

What are the promising strategies for large manufacturers and small local players in the generic injectable market?

Overall, leaders in the generic injectable market are expected to have a wide portfolio and low-cost products, and local players will have truly distinguished offerings. To achieve higher cost savings, government healthcare facilities are now adopting higher utilization of generic injectables in their services.

How are CMOs affecting the growth of the generic injectable market?

Outsourcing manufacturing of generic injectable drugs to CMOs and CDMOs led to significant cost savings among key drug makers, who were facing capital investment issues with high levels of debt.

How is the cost associated with generic injectables hampering market growth in emerging economies?

Heightened competition from low-cost manufacturing countries such as China and India led to the suspension of many products in the segment for economies of scale. This is offering growth opportunity for low-cost manufacturers to gain significant share of the generic injectable market.

Which region is expected to offer lucrative growth opportunities for the generic injectable market?

North America and Europe, being highly mature markets with higher concentration of manufacturers and healthcare resources, are estimated to drive the growth of the global generic injectable market. Furthermore, East Asia and South Asia are expected to be lucrative regions, as a majority of manufacturers of low-cost generic injectables are focusing on establishing facilities in these regions.

How is the competition scenario in the generic injectable market?

Key manufacturers in the generic injectable market such as Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Sanofi S.A. are aiming at inorganic and organic business expansions strategies by entering into mergers, sales agreements, partnerships, and production partnerships with local manufactures from developing economies.


The global generic injectable market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.


  • Monoclonal Antibodies
  • Immunoglobulins
  • Cytokines
  • Insulin
  • Peptide Hormones
  • Blood Factors
  • Peptide Antibiotics
  • Vaccines
  • Small Molecule Antibiotics
  • Chemotherapy Agents
  • Others

Molecule Type

  • Small Molecules
  • Large Molecules


  • Oncology
  • Infectious Diseases
  • Diabetes
  • Blood Disorders
  • Hormonal Disorders
  • Musculoskeletal Disorders
  • CNS Diseases
  • Pain Management
  • Cardiovascular Diseases

Route of Administration

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies


  • North America
  • Europe
  • Latin America
  • South Asia
  • East Asia
  • Oceania
  • Middle East And Africa

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports


Generic Injectable Market